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Abstract
The aim of this study was to assess the prevalence of opioid-induced dysuria in patients with advanced cancer having pain and to
evaluate the possible factors associated. A consecutive sample of 308 patients admitted to an acute pain relief and palliative care
unit during 8 months was surveyed. The exclusion criteria were an expected survival less than 2 months, cognitive disturbances,
bladder catheter in situ, nephrostomy, urether-cutaneostomy, cistostomy, and no pain. At admission and before discharge, the
following data were collected: age, gender, primary cancer, previous pelvic radiotherapy, urinary infection, presence of pelvic
masses, previous pelvic surgery, dysuria, incontinence, previous episodes requiring bladder catheterization, hematuria, local vesi-
cal chemotherapy, recent use of alkaloids, psychiatric disturbances, peripheral neuropathy, use of opioids and their doses and
routes of administration, use of symptomatic treatment for dysuria and its efficacy, need for catheterization, and removal of the
catheter. A total of 170 patients admitted for pain control were surveyed. Most patients (147, 86.5%) were receiving opioids at
admission. The mean age was 65.1 (SD 12.2) and 106 patients were males. Twenty-five patients presented with dysuria at admis-
sion (of which 22 were taking opioids, 14.9%). Eleven patients were inserted a bladder catheter at admission for urine monitoring
and 18 patients had urinary incontinence. During admission, 31 patients presented dysuria (of which 28 were taking opioids, 19%).
The prevalence of dysuria was more frequent in males, in patients presenting pelvic masses or who had pelvic surgery. These
correlations were also confirmed in multivariate analysis. Opioid switching during admission was correlated to the occurrence
of dysuria. Patients with chronic cancer pain receiving opioid therapy present a prevalence of bladder dysfunction of about
15%, which is influenced by several concomitant factors. Further studies should be performed to explore the presence of dysuria
in patients with no pain and not receiving opioids to know the real weight of opioid therapy with respect to other variables1 .
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Opioids are the mainstay of cancer pain management. The
incidence and severity of adverse effects associated with
the administration of opioids can play an important role in the
success or failure of pain management in patients with cancer.
In recent years, opioid-related adverse effects including drow-
siness, nausea and vomiting, constipation, delirium, myoclo-
nus, pruritus, endocrine and immunological changes, and
respiratory depression have been evaluated in critical reviews
and recommendations based on the existing evidence have
been suggested 1-4.
Dysuria has been reported as a bladder dysfunction charac-
terized by disturbances in micturition, incomplete elimination
of urine, or full bladder with inability to void.5 Difficulty with
micturition associated with the use of opioids has seldom been
reported and is more evident during short-term use of opioids6
or particularly when opioids are administered spinally.7,8 An
incidence of 18% urinary retention was found in postoperative
patients and the use of morphine was a significant risk factor.9
It has been reported that the opioid-receptor system is
involved in bladder and urethral function, although the exact
mechanism by which opioids cause urinary retention is incom-
pletely understood.10 Animal and human studies suggest that a
significant component of the effect is owing to a combined
action on the spinal cord and brain, although peripheral effects
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at the bladder may also play a role.8,11 Mechanisms seem to be
mediated through central as well as peripheral opioid receptors
situated in the spinal cord and in the bladder, respectively.
Opioids decrease the force of detrusor contraction, decrease the
sensation of fullness, but probably do not increase sphincter
tone. These effects are reversed by both central and peripheral
opioid antagonists.12
In patients with advanced cancer having chronic cancer
pain, different factors may impair bladder function. Opioid-
induced dysuria has never been assessed in literature and data
regarding their prevalence in patients chronically receiving
systemic opioids for management of cancer pain are lacking.
The aim of this study was to assess the prevalence of opioid-
induced dysuria in a consecutive sample of patients with
advanced cancer having pain and to evaluate the possible risk
factors associated.
Methods
A consecutive sample of 308 patients with pain admitted to an
acute pain relief and palliative care unit during 8 months were
surveyed. The exclusion criteria were an expected survival less
than 2 months, cognitive disturbances, bladder catheter in situ,
nephrostomy, urether-cutaneostomy, cistostomy, and no pain.
Informed consent and institutional approval were obtained.
At admission, based on patient’s history, clinical examina-
tion, and results from recent neuroimaging examinations or
laboratory data, the following data were collected: age, gender,
primary cancer, previous pelvic radiotherapy, urinary infection,
presence of pelvic masses, previous pelvic surgery, dysuria,
incontinence, previous episodes requiring bladder catheteriza-
tion, hematuria, local vescical chemotherapy, recent use of
alkaloids, psychiatric disturbances, peripheral neuropathy,
use of opioids and their doses, and routes of administration.
Before discharging patients home, the following parameters
were recorded: use, doses, and route of administration of
opioids, dysuria, use of symptomatic treatment for dysuria and
its efficacy, need for catheterization, and removal of the catheter
Statistical Analysis
All continuous data are expressed as a mean + standard
deviation of the mean. The association between parameters and
dysuria at admission and during admission was tested by Pear-
son chi-square test and Fisher exact test for frequency analysis,
as appropriate. Furthermore, continuous variables were con-
verted into categorical variables using each cutoff level and the
ratio of the patients with converted variable was analyzed.
All variables were used for the determination of statistically
significant prognostic factors for dysuria. The odds ratio
(OR) and the 95% confidence intervals (CI) for the risk factors
were also calculated. Parameters found to have a P value of less
than .20 in the univariate logistic regression analysis were
entered into stepwise multiple logistic regression model for the
determination of statistically significant, independent, prognos-
tic factors for dysuria. All P values were 2-sided and P values
less than .05 were considered statistically significant. Data were
analyzed by the Epi Info software (version 6.0, Center for
Disease Control and Prevention, Atlanta, Georgia) and SPSS
Software (version 14.0, SPSS Inc, Chicago, Illinois)
Results
Of the 308 patients surveyed, 138 patients were excluded,
because they did not have pain, or due to short life-
expectancy, nephrostomy, urether-cutaneostomy, cistostomy,
and cognitive failure.
The mean age of 170 patients admitted for pain control who
were assessed was 65.1 (SD 12.2) and 106 patients were males.
Most patients (147, 86.5%) were receiving opioids at admis-
sion. Thirty-six male patients had a history of prostatic hyper-
trophia, 7 and 17 patients had received pelvic radiotherapy or
presented pelvic masses, respectively. Twenty-eight patients
had a previous pelvic surgery and four patients had urinary
infection. No patient had a previous bladder instillation of che-
motherapic agents, 6 patients had a previous treatment with
vinca-alkaloids, and 8 patients had psychiatric disorders.
Finally, 25 patients presented dysuria at admission (of which
22 were taking opioids, 14.9%). Eleven patients were inserted
a bladder catheter at admission for urine monitoring and
18 patients had urinary incontinence.
Thirty-one patients presented with dysuria during admis-
sion (of which 28 were taking opioids, 19%). Twenty-seven
patients (18.3%) did not change the opioid dose during admis-
sion, 61 patients (41.5%) increased the dose by 30% to 50%,
20 patients (13.6%) increased the dose by 50% to 100%,
9 patients (6.1%) increased the dose more then 100%, and
44 patients (29.9%) were switched to another opioid. In
6 patients, data were missed. Five patients discontinued
opioids for different reasons. During admission, 26 patients
required a bladder catheterization and in 3 patients it was possi-
ble to remove it before the discharge. Flavossato-propifenazone,
used as symptomatic treatment according to local policy and
availability, was used in 7 patients and was effective in reducing
dysuria in 6 patients.
Data regarding univariate and multivariate logistic regres-
sion are shown in Tables 1 and 2, respectively. The prevalence
of dysuria was higher in males during admission. Patients pre-
senting pelvic masses were more likely to have dysuria at
admission, and patients who had pelvic surgery were more
likely to present with dysuria either at admission or during
admission. These correlations were also confirmed in multi-
variate analysis. Opioid switching during admission was asso-
ciated with the occurrence of dysuria (see Tables 1 and 2).
Discussion
Although the use of opioids for a short period of time, either
systematically or spinally, for example in the postoperative
period, has been reported in literature,8,13 data regarding the
relationship between the use of opioids and dysuria are lacking
in patients with chronic cancer pain. Occasionally, a bladder
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dysfunction during the use of tramadol has been reported,14
but no prospective investigation has ever been performed.
In patients with advanced cancer, there also are several fac-
tors that may impair bladder function. Micturition occurs in
response to afferent signals from the lower urinary tract, and
distension of the bladder wall is the primary stimulus. Thus,
adequate sensory input is the prerequisite for bladder control,
and changes in sensory mechanisms may give rise to distur-
bances in bladder function. This requires coordination of the
smooth muscles of the bladder and urethra and of striated mus-
cles of the outflow region and pelvic floor by a complex neural
control system. The volumes at which sensation to void occurs
wide in individuals2 . Peripheral control of voiding is influenced
by a-adrenergics for the neck of the bladder and by b-adrener-
gics for the dome and mainly depends on the sacral parasympa-
thetic system for detrusor.15 Moreover, it seems that activation
of serotonergic system can suppress voiding by enhancing
efferent control of urethral outlet and inhibiting the parasympa-
thetic excitatory input to the urinary bladder.16
Bladder distension induced by retention may lead to blad-
der catheterization, which is uncomfortable in a setting of
patients with advanced cancer, especially in older men who
may have an underlying element of bladder outlet obstruction
or in patients who may have borderline detrusor function due
to the illness or induced by treatment. Neurological deficits
due to a damage from previous treatment, including surgery
and radiotherapy, other drugs, or preexisting conditions
may reduce bladder ability to void. Most opioids reduce sym-
pathetic tone and enhance parasympathetic tone.7 Moreover,
the pain threshold for the bladder may further contribute
to retention.
The prevalence of dysuria in patients taking opioids was
14.9% and slightly increased during admission with increasing
doses of opioids without attaining significance. More complex
pain situations, requiring multiple opioid regimens such as
switching, were more frequently associated with the occur-
rence of dysuria. Alternately, tolerance to this adverse effect
may develop with one opioid, with changes more likely occur-
ring with switching. The results of the present study also show
that the risk to develop dysuria is associated with different fac-
tors, frequently present in cancer patients. Rather, dysuria
seems to be related to gender but not necessarily age or a
prostatic hypertrophia history, a previous pelvic surgery, the
presence of a pelvic mass, these factors being significant in
multivariate analysis. Thus, multiple conditions related to the
illness or anticancer treatments may influence the occurrence
of micturition disturbances in patients receiving opioids.
This is the first study dealing with the prevalence of dysuria
in patients with advanced cancer having chronic pain receiving
opioids, so that no comparison with existing data is possible.
Most information is gathered from short-period studies. In
postoperative care age, gender, volume of intravenous fluids,
Table 1. Univariate Logistic Regression Analysis Regarding Dysuria at Admission and During Admission and Parameters Examined
Dysuria at Admission Dysuria During Admission
Variables Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value
Age >75 1.31 0.47-3.61 .599 0.94 0.35-2.53 .905
Male 2.00 0.75-5.35 .163 2.85 1.09-7.43 .032
Prostatic hypertrophia 0.76 0.26-2.23 .630 0.97 0.38-2.51 .965
Pelvic radiotherapy 2.24 0.41-12.26 .351 3.32 0.70-15.68 .129
Pelvic mass 3.53 1.16-10.67 .025 1.31 0.39-4.33 .657
Pelvic surgery 5.40 2.11-13.83 .0004 3.59 1.46-8.79 .005
Urinary infection 5.73 0.76-42.80 .088 4.34 0.58-32.14 .150
Previous treatment with vinca-alcaloids 0.0 0.0-0.0 .984 0.0 0.0-0.0 .982
Hematuria 1.35 0.14-12.64 .790 1.03 0.11-9.58 .977
Peripheral neuropathy 0.75 0.08-6.42 .797 1.40 0.26-7.30 .688
Psychiatric disturbances 1.85 0.35-9.76 .465 0.57 0.06-4.86 .612
Opioids at admission 1.06 0.28-3.94 .924 1.42 0.39-5.22 .588
Opioid switching 1.33 0.52-3.35 .544 2.35 1.03-5.36 .040
Table 2. Stepwise Multivariate Logistic Regression Analysis Regarding Dysuria at Admission and During Admission and Parameters Examined
Dysuria at admission Dysuria during admission
Variables Coefficient + SE Odds Ratio 95% CI P Value Coefficient + SE Odds Ratio 95%CI P Value
Male 1.66 (0.6) 5.27 1.36-20.38 .016 1.56 (0.5) 4.79 1.51-15.16 .007
Pelvic surgery 1.96 (0.6) 7.13 2.19-23.15 .0011 1.47 (0.6) 4.37 1.29-14.79 .017
Opioid switching 1.16 (0.4) 3.19 1.27-7.98 .013
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preexisting urinary symptoms, and anorectal and lower urinary
tract surgeries were risk factors for catheterization.6,17 Opioids
modified cystometric measurements, while anti-inflammatory
agents did not induce urodynamic changes. 11
The treatment of opioid-induced dysuria has never been
assessed and only anecdotal suggestions have been provided.
The use of flavossato-propifenazone, used as symptomatic
treatment according to local policy and availability, was rela-
tively effective, although this finding should be explored in
appropriate comparative studies. Moreover, the decision to
start this treatment was based on individual considerations and
patients’ tolerability of the symptom.
In conclusion, patients with chronic cancer pain, receiving
opioid therapy, present a prevalence of bladder dysfunction
of about 15%, which is influenced by several concomitant fac-
tors. Given the complex clinical picture of patients with
advanced cancer, further studies should be performed to
explore the presence of dysuria in patients with no pain and not
receiving opioids or in noncancer patients with chronic pain
receiving opioids to know the real weight of opioid therapy
with respect to other variables3 .
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